

PrPP PDK1

Targeting the PDK1 kinase to protect neurons from the toxicity of several unrelated amyloids

Benoit Schneider^{1,2}, Mathéa Pietri^{1,2}, Vincent Baudouin^{1,2}, Anne Baudry^{1,2}, Zaira E. Arellano-Anaya^{1,2}, Pierre Nioche^{1,2}, Edward Fon³, Odile Kellermann^{1,2} and Jean-Marie Launay⁴ ¹Université Paris Descartes, UMR-1124, F-75006 Paris, France ²Inserm UMR-1124, F-75006 Paris, France ³McGill University, Department of Neurology and Neurosurgery, Montréal, Québec, Canada ⁴AP-HP, Inserm UMR942, Hôpital Lariboisière, F-75010 Paris, France benoit.schneider@parisdescartes.fr

Starting from prion diseases, we uncovered a neurodegenerative cascade that is common to prion and Alzheimer's (AD) diseases. Pathogenic prions (PrP^{Sc}) or neurotoxic beta-amyloid (A β) peptides of the Alzheimer trigger the overactivation of the 3-phosphoinositide-dependent kinase-1 (PDK1), which in turn promotes the phosphorylation and internalization of the α -secretase TACE (ADAM17). Internalized TACE is uncoupled from three main substrates (i) the normal cellular prion protein PrP^C favoring the replication of PrP^{Sc} in prion diseases, (ii) the amyloid precursor protein APP enhancing the production of A β in AD, and (iii) TNF α receptors that accumulate at the plasma membrane and render diseased neurons highly sensitive to TNF α toxicity [1-2].

Deregulation of the PDK1-TACE pathway by PrP^{Sc} or A β originates from the interaction of PrP^{Sc}/A β with PrP^C at the cell surface of neurons and corruption of PrP^C protective signaling function [3].

We recently showed that PrP^{Sc} also corrupts the PrP^C-PDK1-TACE-APP pathway at the root of A β accumulation within a prion-infected context. Accumulated A β does not impact on prion replication nor infectivity. A β , however, displays seedable properties as it can deposit and form A β plaques in the brain of prion-infected mice, but only when a seed of trimers of A β is co-transmitted with PrP^{Sc}. Importantly, brain A β deposition accelerates the death of prion-infected mice [4]. The inhibition of PDK1 is sufficient to target TACE back to the plasma membrane of prion-infected or Alzheimer's neurons, where it recovers its protective cleavage activity. This permits to rescue a normal sensitivity to TNF α , to lower the PrP^{Sc} and A β amyloid loads, and to limit the deposition of A β and formation of A β plaques.

Consequently, the inhibition of PDK1 counteracts motor deficits and prolongs the survival of prion-infected mice and reduces memory and cognitive impairments in AD mouse models. These results posit PDK1 as a therapeutic target to combat both prion and Alzheimer's diseases, which is also supported by a rise in PDK1 activity and reduced TACE α -secretase activity in the postmortem brain of AD subjects [1,2,4].

Beyond prion and Alzheimer's diseases, our current work indicates cross-disease implication of the PrP^C-PDK1-TACE pathocascade in Parkinson's disease and the amyotrophic lateral sclerosis and defines PDK1 as a broad therapeutic target to fight against all these unrelated amyloid-based neurodegenerative diseases.

References:

- [1] Pietri M, Dakowski C, Hannaoui S, Alleaume-Butaux A, Hernandez-Rapp J, Ragagnin A, Mouillet-Richard S, Haik S, Bailly Y, Peyrin JM, Launay JM, Kellermann O, Schneider B. PDK1 decreases TACE-mediated α -secretase activity and promotes disease progression in prion and Alzheimer's diseases. *Nat Med.* 2013 Sep;19(9):1124-31.
- [2] Alleaume-Butaux A, Nicot S, Pietri M, Baudry A, Dakowski C, Tixador P, Ardila-Osorio H, Haeberlé AM, Bailly Y, Peyrin JM, Launay JM, Kellermann O, Schneider B. Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation. *PLoS Pathog.* 2015 Aug 4;11(8):e1005073.
- [3] Ezpeleta J, Boudet-Devaud F, Pietri M, Baudry A, Baudouin V, Alleaume-Butaux A, Dagoneau N, Kellermann O, Launay JM, Schneider B. Protective role of cellular prion protein against TNF α -mediated inflammation through TACE α -secretase. *Sci Rep.* 2017 Aug 9;7(1):7671.
- [4] Ezpeleta J, Baudouin V, Arellano-Anaya ZE, Boudet-Devaud F, Pietri M, Baudry A, Haeberlé AM, Bailly Y, Kellermann O, Launay JM, Schneider B. Production of seedable Amyloid- β peptides in model of prion diseases upon PrP^{Sc}-induced PDK1 overactivation. *Nat Commun.* 2019 Aug 1;10(1):3442.